

Title

Renal Cell Carcinoma / Melanoma

Reference Number: RDF1618-23

Date of Response: 04/07/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma :

Regimen	Trust Total
Avelumab + Axitinib	7
Axinitib	0
Cabozantinib	16
Everolimus	0
Ipilimumab monotherapy	0
Lenvatinib + Everolimus	* <5
Nivolumab monotherapy	19
Nivolumab + Cabozantinib	0
Nivolumab + Ipilimumab	* <5
Pazopanib	* <5
Pembrolizumab + Axitinib	0
Pembrolizumab + Lenvatinib	* <5
Pembrolizumab monotherapy	0
Radiotherapy only	0
Sunitinib	6
Temsirolimus	0
Tivozanib	0
Other active systemic anti-cancer therapy	0
Palliative Care only*	* <5

*We cannot say for certain that these patients were ONLY treated with palliative care, only that they have received palliative care.

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

Regimen	Trust Total
Cobimetinib	0
Dabrafenib	*<5
Dabrafenib AND Trametinib	13
Dacarbazine	0
Encorafenib AND Binimetinib	6
Ipilimumab	*<5
Ipilimumab AND Nivolumab	7
Nivolumab	13
Pembrolizumab	62
Trametinib	0
Vemurafenib	0
Vemurafenib AND Cobimetinib	0
Other active systemic anti-cancer therapy	6
Palliative care only*	*<5

*We cannot say for certain that these patients were ONLY treated with palliative care, only that they have received palliative care.

**Based on latest 3 months SACT data February 2023 to April 2023

***<5 - Section 40 (2) for question 1 and 2:**

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients/staff and should not be published.

Q3. Does your trust participate in any clinical trials for the treatment of Melanoma?

Yes.

If so please provide the name of each trial and number of patients that are taking part?

Trial name	Description	Total patients
DANTE	Duration of Anti-PD1 therapy for melanoma	5
COMBI-AD	dabrafenib + trametinib vs placebo in adjuvant BRAF+ cutaneous melanoma	5